To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Oral Tramadol/Dexketoprofen & Injectable Paracetamol + Tramadol: A Meta-Analysis

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
October 2024

Oral Tramadol/Dexketoprofen & Injectable Paracetamol + Tramadol: A Meta-Analysis

Vol: 306| Issue: 10| Number:18| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Pain management after total hip arthroplasty: comparative study of analgesic efficacy and tolerability between oral tramadol/dexketoprofen and injectable paracetamol + tramadol.

Hip Int . 2024 May;34(3):304-310.

Contributing Authors:
GA Macheras D Tzefronis C Argyrou E Nikolakopoulou A Galvez Miravete TS Karachalios

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

320 patients with primary hip osteoarthritis undergoing total hip arthroplasty were randomized to receive either oral tramadol/dexketoprofen (Group A, n=188) or intravenous paracetamol plus tramadol (Group B, n=135). The primary outcome of interest was the reduction in pain intensity measured by the visual analogue scale (VAS) over 48 hours postoperatively. Secondary outcomes included the need for...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue